Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic bone marrow transplantation. Immunosuppressive treatment regimens carry the potential of causing severe morbidity and mortality, so that additional modes of therapy with fewer sideeffects are clearly needed. Five cGVHD patients (sclerodermoid cGVHD in two patients, lichenoid cGVHD in one patient and intraoral cGVHD in two patients), who had not responded to standard immunosuppressive drugs, were treated with adjuvant UVB phototherapy. The patient with lichenoid cGVHD experienced complete clearing of cutaneous lesions, whereas both patients with sclerodermoid cGVHD experienced significant relief of pruritus, but showed no change of the sclerodermoid skin lesions. Intraoral lesions cleared in one patient. The effects of UVB phototherapy were furthermore documented by measurement of skin viscoelasticity and mouth opening. No sideeffects were encountered. This preliminary study suggests that UVB phototherapy is useful as an adjuvant therapeutic modality in intraoral and cutaneous lichenoid cGVHD. Keywords: graft-versus-host disease; UVB; bone marrow transplantation Chronic graft-versus-host disease (cGVHD) remains a major complication of allogeneic bone marrow transplantation that develops in more than 25% of patients. Two clinical forms of cGVHD are distinguished: Lichenoid cGVHD develops within 3 or more months after transplantation, and is characterized by violaceous, lichenoid papules usually starting at the extremities. Mucous membranes are often affected as manifested by leukoplakia, lichen planuslike lesions and erosions. Sicca symptoms, pain and dysphagia are common when larger areas of the oral mucosa are involved. The more advanced sclerodermoid cGVHD is distinguished by plaques of dermal sclerosis resembling morphea, and eventually by generalized scleroderma, often resulting in joint contractures. Treatment with immunosuppressive regimens carries the potential of severe morbidity and mortality, so that additional modes of therapy with
fewer side-effects that would improve both the survival and the quality of life of the patients, are clearly needed.
Non-ionizing radiation has the capacity to profoundly modify immunity and immunogenicity both systemically and locally in the skin. Photochemotherapy denotes the combination of an exogenous photosensitizer such as 8-methoxypsoralen and long wave ultraviolet A (320-400 nm) radiation (PUVA). PUVA treatment based on psoralen-induced photosensitisation to UVA exposure has successfully been exploited as adjuvant therapy for refractory cGVHD.
1,2 Shorter wave UVB radiation (280-320 nm), which is extensively used to treat a wide range of inflammatory skin diseases, does not entail prior administration of a photosensitizer, and can therefore safely be given to patients who do not tolerate psoralen, eg because of dysfunction of the liver. We report here our experience with UVB phototherapy in patients with cutaneous and intraoral manifestations of cGVHD.
Patients and methods

Patients
Three patients with cutaneous cGVHD and two patients with only intraoral disease who failed to respond to conventional therapy, were treated with UVB phototherapy after giving informed consent. Clinical profiles of the patients are given in Table 1 .
Phototherapy
UVB phototherapy was administered by means of a Waldmann UV 8001 K (Villingen-Schwenningen, Germany) cabin equipped with 13 F85/100 UVB lamps. Treatments were given two to three times weekly. All patients were skin type II or III, and the starting dose was determined by the minimal erythema dose (MED) with increments of 0.02 mJ/cm 2 every two treatments. In one patient, (NP), the left side of the chest was shielded during all phototherapy sessions as a control for the efficacy of UVB treatment. Duration of treatment was determined individually based on clinical improvement or absence of response during at least 2 months of treatment. Patients with intraoral cGVHD were administered UVB using a Waldmann UV 180 hand unit equipped with 8 F15/T8 UVB lamps. The face was totally covered except for the mouth which was placed in direct contact with the glass surface of the UVB unit. In order to ensure homogeneous irradiation of all affected mucosal surfaces, each treatment session was divided into with increments of 0.02 mJ/cm 2 every three treatments. Two to three treatments were given weekly.
Treatment response
Therapeutic response was monitored by weekly clinical examinations by a dermatologist, a hematologist and an oral surgeon. In addition to routine hematological and biochemical tests as required by the basic disease and the simultaneous immunosuppressive treatment, a whole body clinical skin examination was performed. In order to evaluate objectively skin response to treatment, the mechanical properties of the skin were followed using a viscoelasticity skin analyzer (VESA). 3 This device measures the speed of mechanical elastic wave propagation along the skin that is proportional to the stiffness of the skin and inversely proportional to the skin viscoelasticity. To obtain an objective expression of oral therapeutic response, the weekly physical examination of oral soft tissues was supplemented by measurement of mouth opening (the vertical distance between the upper central and the lower central teeth when the mouth is opened maximally).
Results
The two patients with sclerodermoid cGVHD responded to UVB phototherapy only by reduction of dryness and pruritus, as indicated by a subjective feeling of comfort and by reduction in the use of topical emollients. The VESA measurements in these patients showed no change of skin stiffness during the entire treatment period (data not shown). In contrast, the patient with lichenoid cGVHD (NP) showed complete clinical remission of his cGVHD skin lesions (Figure 1) . Correspondingly, the stiffness of the skin on the UVB irradiated side of the body was found to decrease rapidly as demonstrated by VESA measurements ( Figure 2 ). Of special interest is the fact that although the mechanical properties of the skin of the UVB-shielded side of the chest also improved, the changes started later than on the UVB exposed side. At follow-up 18 months after cessation of UVB therapy, the patient remained free of cutaneous lesions.
Both patients with intraoral cGVHD improved markedly during the first weeks of treatment with regard to subjective symptoms such as oral pain and inconvenience during eating and talking. In one patient (MZ), continued treatment also resulted in objective clinical improvement. Thus the floor of the mouth, the palate, and the attached gingiva were intact and the tongue revealed erosions and erythema limited to its anterior part only (Figure 3 ). The patients were followed for 3 months after termination of oral UVB treatment with no deterioration in the oral lesions. The second patient with intraoral cGVHD (YR) did not continue to improve, and he decided to discontinue treatment after 8 weeks. Measurement of mouth opening confirmed the subjective signs of improvement: patient MZ showed an impressive improvement of up to 0.7 cm, whereas patient YR had no improvement in his mouth opening ability. However, this patient suffered from arthritis of the tempo- Measurements were performed using a viscoelasticity skin analyzer that measures the speed of mechanical elastic wave propagation along the skin, which is proportional to the stiffness of the skin. Triplicate measurements were performed on nine points of the chest with wave propagation in vertical and horizontal directions. Average and standard deviations are indicated.
mandibular joints, which might have prevented improvement of mouth opening in spite of reduction of soft tissue stiffness following UVB.
Discussion
We have treated three patients with UVB phototherapy for refractory cutaneous cGVHD. Although all patients experienced some benefit from the treatment, only the patient with lichenoid cGVHD responded significantly. The lack of effect on sclerodermoid cGVHD might be explained by the inability of UVB radiation to reach the dermis, which is the seat of the histological and biochemical pathological processes that characterize sclerodermoid cGVHD. In contrast, the major pathological interphase changes in lichenoid cGVHD are located more superficially, and are reached by the UVB radiation. Evaluation of viscoelasticity and mouth opening was performed in order to obtain objective parameters of improvement for patients with cutaneous and intraoral lesions, respectively. Skin viscoelasticity was measured during treatment and appears to be a useful parameter of response to UVB phototherapy. This is dramatically demonstrated by the finding that the area that was shielded during irradiation exhibited a clear delay with regard to improved viscoelasticity compared to the non-shielded, irradiated area (Figure 2) . Furthermore, the delay in viscoelasticity response indicates that the cause of clinical response is the UVB treatment and not the concurrent immunosuppressive treatment, which was given systemically, and did not spare the area with delayed response. The fact that even non-irradiated skin improved can be explained by the systemic effects of UVB as discussed below.
Except for occasional mild erythema, no phototoxicity reactions were encountered. Of special interest is the fact that in none of the patients did UVB phototherapy aggravate the cGVHD, nor did any symptoms of drug photosensitization occur in spite of the multiple drugs ingested by most of the patients. A major concern, at least theoretically, is the carcinogenic effect of UV light; in patients with psoriasis treated with high-dose PUVA photochemotherapy, the risk of developing squamous cell carcinoma, basal cell carcinoma, or malignant melanoma is significantly increased.
Interestingly, although UVB irradiation is more carcinogenic than PUVA in laboratory animals, the opposite appears to be true in UVB-treated psoriasis patients. Thus no significant increase in the risk of squamous cell carcinoma or basal cell carcinoma has been associated with long-term exposure of psoriasis patients to UVB phototherapy. 5 Whether such data from immunocompetent psoriasis patients can be extrapolated to immunocompromised cGVHD patients, is, however, questionable. None of our patients developed skin cancer or any preneoplastic lesions. However, the short observation period does not allow the conclusion that UVB is not carcinogenic in our patients, and continued clinical monitoring of patients for skin cancer is required.
Use of UVB phototherapy in the management of cGVHD has previously been reported by van Dooren-Greebe et al, 6 who described a 45-year-old man with cGVHD characterized by generalized erythema, papules, scaling, and hyperpigmentation. Remission was induced by as little as 0.6 J/cm 2 , but the patient relapsed 3 weeks after discontinuation of phototherapy. A second and permanent remission was reached after a total UVB dose of 4 J/cm 2 . Although it is impossible from the clinical description to determine whether this patient presented with lichenoid or sclerodermoid disease, it is striking that the patient responded completely to a relatively small total UVB dose. Aubin et al 1 reported one patient with lichenoid cGVHD treated with UVB who entered complete remission. This patient received a total UVB dose of 25 J/cm 2 delivered over 62 treatment sessions. In the present study lichenoid cGVHD appears to be more susceptible to UVB phototherapy than is sclerodermoid cGVHD. This is in accordance with the experience with PUVA photochemotherapy for cGVHD. Thus, Vogelsang et al 2 obtained complete or partial remissions in 10 of 11 lichenoid cGVHD patients, whereas none of the three patients with sclerodermoid cGVHD responded. Likewise, Aubin et al 1 successfully treated three of five lichenoid cGVHD patients (one complete and two partial remissions). Surprisingly, even the single patient in their series with sclerodermoid cGVHD responded well to PUVA photochemotherapy.
Intraoral cGVHD appears to be susceptible to both UVB and PUVA therapy. Vogelsang et al 2 treated seven patients with PUVA and obtained complete remission in four and partial remission in two. Due to the different kind of irradiation it is not possible to compare the total doses of the two regimens.
It is only possible to speculate about the mechanisms of phototherapy in the treatment of cGVHD. UV light exhibits profound effects on systemic and cutaneous immunoregulatory mechanisms, primarily via inactivation of Langerhans cell antigen presenting capacity and secretion of immunosuppressive cytokines. 7 The balance between type 1 and type 2 cytokines has been hypothesized to govern the extent to which GVHD develops after allogeneic bone marrow transplantation. 8 The ability of UVB light to induce IL-10 activity in human epidermal cells 9 could account for a shift in the direction of a type 2 response, tending to limit the immune processes leading to GVHD. Whereas such immune mechanisms can account for an effect of UVB in preventing development and progression of GVHD, they cannot explain the beneficial effect of UVB on established disease. Fisher et al 10 recently showed that matrix-degrading metalloproteinases such as interstitial collagenase, stromelysin, and gelatinase activity are induced in human skin after exposure to even small doses of UVB light in vivo. Furthermore, Wlascheck et al 11 found that UVA radiation of cultured human fibroblasts induces IL-6, followed by increased collagenase activity. This experiment suggested a causative relationship between the two activities, namely that UV light induces IL-6 in dermal fibroblasts, which in turn regulates the catabolic pathway of collagen metabolism by induction of the synthesis of collagenase and maybe also other metalloproteinases. Such mechanisms might partly explain the beneficial effect of UVB light on established cGVHD.
In summary, this preliminary study suggests that UVB phototherapy is useful as an adjuvant therapeutic modality in cutaneous lichenoid cGVHD and in intraoral cGVHD. The treatment appears to have no side-effects, and to be advantageous in patients with impaired liver function who cannot tolerate PUVA treatment or other toxic regimens.
Although UVB phototherapy appears to be most effective early in the disease course, the optimal time for its initiation has not yet been established. Our current understanding of the immunopathogenesis of GVHD suggests that UV therapy might even have a role in GVHD prophylaxis. Additional larger scale comparative studies will have to be performed to determine the role of UVB phototherapy in prevention and treatment of cGVHD.
